Browsing: PediatricYoung

Diagnosis

Tisagenlecleucel Shows Durable Efficacy in Pediatric/Young Adult ALL

By NewsCancerAugust 7, 20260

Tisagenlecleucel (tisa-cel; Kymriah) continued to demonstrate durable responses and a manageable long-term safety profile in pediatric and young adult patients…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

What Makes an Optimal CAR T-Cell Therapy Candidate in Multiple Myeloma

AI-based augmentation of oncology clinical trials

Tisagenlecleucel Shows Durable Efficacy in Pediatric/Young Adult ALL

Browsing: PediatricYoung

Tisagenlecleucel Shows Durable Efficacy in Pediatric/Young Adult ALL

What Makes an Optimal CAR T-Cell Therapy Candidate in Multiple Myeloma

AI-based augmentation of oncology clinical trials

Tisagenlecleucel Shows Durable Efficacy in Pediatric/Young Adult ALL

Changing Chemotherapy Delivery in BCG-Unresponsive Bladder Cancer

What Makes an Optimal CAR T-Cell Therapy Candidate in Multiple Myeloma

AI-based augmentation of oncology clinical trials

Tisagenlecleucel Shows Durable Efficacy in Pediatric/Young Adult ALL

Changing Chemotherapy Delivery in BCG-Unresponsive Bladder Cancer

Latest Post

What Makes an Optimal CAR T-Cell Therapy Candidate in Multiple Myeloma

AI-based augmentation of oncology clinical trials

Tisagenlecleucel Shows Durable Efficacy in Pediatric/Young Adult ALL

Subscribe to Updates

What's Hot

Browsing: PediatricYoung